Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

Second generation epigenetic aging clock

Time frame · Baseline, week 33, week 57

PCGrimAge will be used to study the measured epigetic age and differences with chronological age in years.

Third generation epigenetic aging clock

Time frame · Baseline, week 33, week 57

DunedinPACE will be used to assess the pace of aging, quantifying years of physiological decline per chronological year.

Intrahepatic triglycerides

Time frame · Baseline, week 33, week 57

Intrahepatic triglycerides will be measured using Magnetic Resonance Imaging Proton Density Fat Fraction (MRI PDFF).

Change in body composition assessed by dual-energy X-ray absorptiometry (DXA)

Time frame · Baseline, week 33, week 57

Lean body mass and fat mass will be measured in kilograms.

Change from baseline in body fat mass measured by bioelectrical impedance analysis (BIA)

Time frame · Baseline, week 33, week 57

Bioelectrical impedance analysis will be used to assess fat mass in kilograms.

Patient reported outcome

Time frame · Baseline, week 33, week 57

Patient reported outcome will be assessed using HIV symptom index

Drinking habits

Time frame · Baseline, week 33, week 57

Alcohol Use Disorders Identification Test (AUDIT) will be used to assess drinking habits for all participants.

Body weight

Time frame · Baseline, week 8, week 13, week 21, week 33, week 57

Body weight will be measured in kilograms.

Waist circumference

Time frame · Baseline, week 8, week 13, week 21, week 33, week 57

Waist circumference will be measured in centimeters

Inflammation markers

Time frame · Baseline, week 33, week 57

C-reactive protein will be measured in mg/dL.

Total bilirubin

Time frame · Baseline, week 33, week 57

Total bilirubin will be measured in mg/dL.

Alanine transaminase

Time frame · Baseline, week 33, week 57

ALT will be measured in U/L.